Trials / Conditions / Primary Immune Deficiency

Primary Immune Deficiency

23 registered clinical trials studyying Primary Immune Deficiency — 3 currently recruiting.

Status	Trial	Sponsor	Phase
Unknown	Evaluating Bronchodilator Response in Patients With Bronchiectasis NCT05932316	Rambam Health Care Campus	N/A
Completed	Evaluation of Adult Patients With Immunodeficiency Within the Scope of the ICF NCT06014463	Hacettepe University	—
Unknown	An Open Label, Multicenter Study to Evaluate the Pharmacokinetics, Efficacy and Safety of ASCENIV™ (IGIV) in P NCT05070455	ADMA Biologics, Inc.	Phase 4
Unknown	A Prospective Monocentric Study to Assess the Concordance of Lung MRI Compared to Chest CT Scan to Assess the NCT05476653	Hopital Foch	N/A
Active Not Recruiting	COVID-19 Vaccine Responses in PIDD Subjects NCT05321407	Duke University	—
Active Not Recruiting	Study to Evaluate the Pharmacokinetics, Efficacy, Tolerability, and Safety of Subcutaneous Human Immunoglobuli NCT04640142	Octapharma	Phase 3
Completed	Characterizing the Upper Airway Manifestations in Primary Ciliary Dyskinesia and Primary Immunodeficiencies NCT04919018	University of North Carolina, Chapel Hill	—
Recruiting	Biologics And Clinical Immunology Cohort at Sinai NCT04784364	Icahn School of Medicine at Mount Sinai	—
Active Not Recruiting	Study of Immune Globulin Intravenous (Human) GC5107 in Pediatric Subjects With Primary Humoral Immunodeficienc NCT04565015	GC Biopharma Corp	Phase 3
Completed	Defining the Genetic Etiology of Suppurative Lung Disease in Children and Adults NCT04702243	University of North Carolina, Chapel Hill	—
Completed	Primitive Immunodeficiency and Pregnancy NCT04581460	Assistance Publique - Hôpitaux de Paris	—
Recruiting	COVID-19 in PID Survey NCT04459689	Imagine Institute	—
Unknown	Transfer of Effector Memory T Cells (Tem) Following Allogeneic Stem Cell Transplantation NCT03836690	University College, London	Phase 1
Completed	Study of Immune Deficiency Patients Treated With Subcutaneous Immunoglobulin (IgPro20, Hizentra®) on Weekly an NCT02711228	CSL Behring	Phase 4
Unknown	Determinants of Health Status and Quality of Life in Patients With Primary Immunodeficiencies Inhereted Diagno NCT02868333	Assistance Publique Hopitaux De Marseille	—
Completed	Multicenter Study of Long-Term Clinical Outcomes of Subcutaneous Immune Globulin IgPro20 in Subjects With Prim NCT01461018	CSL Behring	Phase 3
Completed	Study of Subcutaneous Immune Globulin in Patients Requiring IgG Replacement Therapy (Japan Study) NCT01199705	CSL Behring	Phase 3
Completed	Retrospective Chart Review of Subcutaneous IgG Use in Infants NCT01166074	CSL Behring	—
Completed	Extension Study of Subcutaneous Immunoglobulin Human in Patients With Primary Immunodeficiency (PID) NCT00719680	CSL Behring	Phase 3
Completed	Safety Study of Subcutaneous Ig NextGen 16% in Patients With Primary Immunodeficiency NCT00680446	CSL Limited	Phase 3
Recruiting	Screening Protocol for Genetic Diseases of Lymphocyte Homeostasis and Programmed Cell Death NCT00246857	National Institute of Allergy and Infectious Diseases (NIAID)	—
Completed	Study of Subcutaneous Immunoglobulin in Patients With PID Requiring IgG Replacement Therapy NCT00419341	CSL Behring	Phase 3
Terminated	Antibody Production in Immune Disorders NCT00023504	National Institute of Allergy and Infectious Diseases (NIAID)	Phase 4